Andrew L. Kung

48.1k total citations · 14 hit papers
285 papers, 24.2k citations indexed

About

Andrew L. Kung is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Andrew L. Kung has authored 285 papers receiving a total of 24.2k indexed citations (citations by other indexed papers that have themselves been cited), including 170 papers in Molecular Biology, 89 papers in Hematology and 81 papers in Oncology. Recurrent topics in Andrew L. Kung's work include Protein Degradation and Inhibitors (41 papers), Acute Myeloid Leukemia Research (38 papers) and Cancer, Hypoxia, and Metabolism (31 papers). Andrew L. Kung is often cited by papers focused on Protein Degradation and Inhibitors (41 papers), Acute Myeloid Leukemia Research (38 papers) and Cancer, Hypoxia, and Metabolism (31 papers). Andrew L. Kung collaborates with scholars based in United States, Switzerland and United Kingdom. Andrew L. Kung's co-authors include David M. Livingston, Renee D. Wright, James E. Bradner, Gerhard Wagner, Gregory L. Verdine, Scott A. Armstrong, Steven W. Sherwood, Scott J. Rodig, Loren D. Walensky and Stanley J. Korsmeyer and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Andrew L. Kung

273 papers receiving 23.8k citations

Hit Papers

Activation of Apoptosis i... 2000 2026 2008 2017 2004 2005 2001 2011 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
    2004 1.1k citations Andrew L. Kung, Renee D. Wright et al. profile →
  2. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing
    2005 995 citations Andrew L. Kung et al. profile →
  3. Role of T-bet in Commitment of T H 1 Cells Before IL-12-Dependent Selection
    2001 672 citations Andrew L. Kung et al. profile →
  4. MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
    2011 642 citations Sridhar Vempati, Andrei V. Krivtsov et al. profile →
  5. Direct inhibition of the NOTCH transcription factor complex
    2009 619 citations Tina Davis, Jon C. Aster et al. profile →
  6. Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
    2013 610 citations Andrew L. Kung et al. profile →
  7. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
    2013 550 citations Jun Qi, Andrew L. Kung et al. profile →
  8. SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
    2011 537 citations Amanda L. Christie, Jon C. Aster et al. profile →
  9. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
    2003 511 citations Joshua B. Rubin, Andrew L. Kung et al. Proceedings of the National Academy of Sciences profile →
  10. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
    2012 488 citations Andrew L. Kung, James E. Bradner et al. profile →
  11. Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
    2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →
  12. NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
    2014 453 citations Andrew L. Kung, James E. Bradner et al. profile →
  13. Suppression of tumor growth through disruption of hypoxia-inducible transcription
    2000 436 citations Andrew L. Kung, William G. Kaelin et al. profile →
  14. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
    2014 375 citations Amanda L. Christie, Andrew L. Kung et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew L. Kung United States 81 16.6k 6.6k 4.6k 4.1k 2.9k 285 24.2k
Tannishtha Reya United States 38 13.8k 0.8× 7.5k 1.1× 3.7k 0.8× 2.5k 0.6× 2.3k 0.8× 67 21.0k
Carsten Müller‐Tidow Germany 64 11.4k 0.7× 4.3k 0.7× 4.3k 0.9× 5.3k 1.3× 2.2k 0.8× 492 18.0k
Steven Grant United States 79 16.7k 1.0× 6.3k 1.0× 2.3k 0.5× 3.6k 0.9× 2.2k 0.7× 451 23.2k
James E. Bradner United States 86 24.1k 1.4× 6.3k 1.0× 2.3k 0.5× 5.8k 1.4× 1.8k 0.6× 217 28.8k
Adolfo A. Ferrando United States 65 15.8k 1.0× 3.8k 0.6× 8.6k 1.9× 4.4k 1.1× 2.9k 1.0× 164 23.7k
Julie Teruya‐Feldstein United States 77 13.1k 0.8× 7.6k 1.2× 5.5k 1.2× 2.1k 0.5× 3.2k 1.1× 216 22.2k
C Peschle Italy 75 13.2k 0.8× 6.1k 0.9× 5.3k 1.2× 4.5k 1.1× 3.8k 1.3× 321 22.7k
Giuseppe Basso Italy 73 10.1k 0.6× 4.4k 0.7× 2.9k 0.6× 6.8k 1.6× 3.7k 1.3× 536 24.1k
David C.S. Huang Australia 82 20.4k 1.2× 6.2k 0.9× 2.5k 0.6× 2.8k 0.7× 6.7k 2.3× 236 28.2k
Dario C. Altieri United States 94 22.4k 1.3× 9.0k 1.4× 4.5k 1.0× 2.4k 0.6× 5.8k 2.0× 256 31.2k

Countries citing papers authored by Andrew L. Kung

Since Specialization
Citations

This map shows the geographic impact of Andrew L. Kung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew L. Kung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew L. Kung more than expected).

Fields of papers citing papers by Andrew L. Kung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew L. Kung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew L. Kung. The network helps show where Andrew L. Kung may publish in the future.

Co-authorship network of co-authors of Andrew L. Kung

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew L. Kung. A scholar is included among the top collaborators of Andrew L. Kung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew L. Kung. Andrew L. Kung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
DeSisto, John, Patrick Flannery, Amrita Pathak, et al.. (2019). Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma. Molecular Cancer Therapeutics. 19(2). 540–551. 18 indexed citations
2.
Giulino‐Roth, Lisa, Tanner C. Dalton, Jennifer Totonchy, et al.. (2017). Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Molecular Cancer Therapeutics. 16(9). 1779–1790. 60 indexed citations
3.
Davé, Utpal P., Irina V. Lebedeva, Yao Shen, et al.. (2017). PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature. Molecular Cancer Therapeutics. 16(10). 2069–2082. 7 indexed citations
4.
Pikman, Yana, Gabriela Alexe, Giovanni Roti, et al.. (2016). Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research. 23(4). 1012–1024. 81 indexed citations
5.
Stubbs, Matthew C., Won-Il Kim, Tina Davis, et al.. (2015). Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research. 21(10). 2348–2358. 59 indexed citations
6.
Sicińska, Ewa, Jeffrey T. Czaplinski, Stephen P. Remillard, et al.. (2014). Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo. Molecular Cancer Therapeutics. 13(9). 2184–2193. 98 indexed citations
7.
Zerbini, Luiz F., Manoj Bhasin, Jaira F. de Vasconcellos, et al.. (2014). Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer. Molecular Cancer Therapeutics. 13(7). 1929–1941. 49 indexed citations
8.
Chen, Zhao, Esra A. Akbay, Oliver R. Mikse, et al.. (2013). Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK -Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance. Clinical Cancer Research. 20(5). 1204–1211. 51 indexed citations
9.
Puissant, Alexandre, Stacey M. Frumm, Gabriela Alexe, et al.. (2013). Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery. 3(3). 308–323. 457 indexed citations breakdown →
10.
Shimamura, Takeshi, Zhao Chen, Margaret Soucheray, et al.. (2013). Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6183–6192. 158 indexed citations
11.
O’Neill, Allison F., Jason L.J. Dearling, Yuchuan Wang, et al.. (2013). Targeted Imaging of Ewing Sarcoma in Preclinical Models Using a 64Cu-Labeled Anti-CD99 Antibody. Clinical Cancer Research. 20(3). 678–687. 17 indexed citations
12.
Crompton, Brian D., Aaron R. Thorner, Amanda L. Christie, et al.. (2013). High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma. Cancer Research. 73(9). 2873–2883. 42 indexed citations
13.
McMillin, Douglas W., Hannah M. Jacobs, Jake Delmore, et al.. (2012). Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma. Molecular Cancer Therapeutics. 11(4). 942–951. 46 indexed citations
14.
Schwartz, Brian E., Matthias D. Hofer, Madeleine E. Lemieux, et al.. (2011). Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. Cancer Research. 71(7). 2686–2696. 156 indexed citations
15.
Weisberg, Ellen, Hwan Geun Choi, Rosemary Barrett, et al.. (2010). Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors. Molecular Cancer Therapeutics. 9(9). 2468–2477. 12 indexed citations
16.
Kim, William Y., Samanthi A. Perera, Bing Zhou, et al.. (2009). HIF2α cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation. 119(8). 2160–2170. 120 indexed citations
17.
Weisberg, Ellen, Renee D. Wright, Douglas W. McMillin, et al.. (2008). Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Therapeutics. 7(5). 1121–1129. 60 indexed citations
18.
Woerner, B. Mark, Nicole M. Warrington, Andrew L. Kung, Arie Perry, & Joshua B. Rubin. (2005). Widespread CXCR4 Activation in Astrocytomas Revealed by Phospho-CXCR4-Specific Antibodies. Cancer Research. 65(24). 11392–11399. 96 indexed citations
19.
Mitsiades, Constantine S., Nicholas Mitsiades, Andrew L. Kung, Ciaran J. McMullan, & Kenneth C. Anderson. (2004). IGF-II is a major proliferative/anti-apoptotic cytokine and a therapeutic target in multiple myeloma, other hematologic neoplasias and solid tumors.. Cancer Research. 64. 559–560. 1 indexed citations
20.
Rubin, Joshua B., Andrew L. Kung, Robyn S. Klein, et al.. (2003). A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proceedings of the National Academy of Sciences. 100(23). 13513–13518. 511 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tannishtha Reya Breakdown of academic impact, for papers by Carsten Müller‐Tidow Breakdown of academic impact, for papers by Steven Grant Breakdown of academic impact, for papers by James E. Bradner Breakdown of academic impact, for papers by Adolfo A. Ferrando Breakdown of academic impact, for papers by Julie Teruya‐Feldstein Breakdown of academic impact, for papers by C Peschle Breakdown of academic impact, for papers by Giuseppe Basso Breakdown of academic impact, for papers by David C.S. Huang Breakdown of academic impact, for papers by Dario C. Altieri
Rankless by CCL
2026